The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Rivaroxaban-Global Market Insights and Sales Trends 2025
Synopsis
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global Rivaroxaban market size is expected to reach US$ 13970 million by 2029, growing at a CAGR of 8.2% from 2023 to 2029. The market is mainly driven by the significant applications of Rivaroxaban in various end use industries. The expanding demands from the Acute Coronary Syndrome (ACS) and Venous Thromboembolism (VTE), are propelling Rivaroxaban market. 2.5 mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 10 mg segment is estimated at % CAGR for the next seven-year period.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rivaroxaban, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rivaroxaban market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rivaroxaban market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rivaroxaban sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rivaroxaban covered in this report include Bayer and J&J etc.
The global Rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
J&J
Global Rivaroxaban market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rivaroxaban market, Segment by Type:
2.5 mg
10 mg
15 mg
20 mg
Global Rivaroxaban market, by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Rivaroxaban is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
The global Rivaroxaban market size is expected to reach US$ 13970 million by 2029, growing at a CAGR of 8.2% from 2023 to 2029. The market is mainly driven by the significant applications of Rivaroxaban in various end use industries. The expanding demands from the Acute Coronary Syndrome (ACS) and Venous Thromboembolism (VTE), are propelling Rivaroxaban market. 2.5 mg, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the 10 mg segment is estimated at % CAGR for the next seven-year period.
The major players in global Prom Dresses market include Bayer, Johnson and Johnson, etc. The top 2 players occupy nearly 100% of the market. Europe is the main market, and occupies nearly 100% of the global market. 10 mg is the main type, with a share over 30%. Venous Thromboembolism (VTE) is the main application, which holds a share about 85%.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Rivaroxaban, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Rivaroxaban market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Rivaroxaban market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Rivaroxaban sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Rivaroxaban covered in this report include Bayer and J&J etc.
The global Rivaroxaban market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
Bayer
J&J
Global Rivaroxaban market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Rivaroxaban market, Segment by Type:
2.5 mg
10 mg
15 mg
20 mg
Global Rivaroxaban market, by Application
Acute Coronary Syndrome (ACS)
Venous Thromboembolism (VTE)
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of Rivaroxaban manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of Rivaroxaban in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 Rivaroxaban Market Overview
1.1 Rivaroxaban Product Overview
1.2 Rivaroxaban Market Segment by Type
1.2.1 2.5 mg
1.2.2 10 mg
1.2.3 15 mg
1.2.4 20 mg
1.3 Global Rivaroxaban Market Size by Type
1.3.1 Global Rivaroxaban Market Size Overview by Type (2018-2029)
1.3.2 Global Rivaroxaban Historic Market Size Review by Type (2018-2023)
1.3.3 Global Rivaroxaban Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America Rivaroxaban Sales Breakdown by Type (2018-2023)
1.4.2 Europe Rivaroxaban Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific Rivaroxaban Sales Breakdown by Type (2018-2023)
1.4.4 Latin America Rivaroxaban Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa Rivaroxaban Sales Breakdown by Type (2018-2023)
2 Global Rivaroxaban Market Competition by Company
2.1 Global Top Players by Rivaroxaban Sales (2018-2023)
2.2 Global Top Players by Rivaroxaban Revenue (2018-2023)
2.3 Global Top Players by Rivaroxaban Price (2018-2023)
2.4 Global Top Manufacturers Rivaroxaban Manufacturing Base Distribution, Sales Area, Product Type
2.5 Rivaroxaban Market Competitive Situation and Trends
2.5.1 Rivaroxaban Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by Rivaroxaban Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Rivaroxaban as of 2022)
2.7 Date of Key Manufacturers Enter into Rivaroxaban Market
2.8 Key Manufacturers Rivaroxaban Product Offered
2.9 Mergers & Acquisitions, Expansion
3 Rivaroxaban Status and Outlook by Region
3.1 Global Rivaroxaban Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global Rivaroxaban Historic Market Size by Region
3.2.1 Global Rivaroxaban Sales in Volume by Region (2018-2023)
3.2.2 Global Rivaroxaban Sales in Value by Region (2018-2023)
3.2.3 Global Rivaroxaban Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global Rivaroxaban Forecasted Market Size by Region
3.3.1 Global Rivaroxaban Sales in Volume by Region (2024-2029)
3.3.2 Global Rivaroxaban Sales in Value by Region (2024-2029)
3.3.3 Global Rivaroxaban Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global Rivaroxaban by Application
4.1 Rivaroxaban Market Segment by Application
4.1.1 Acute Coronary Syndrome (ACS)
4.1.2 Venous Thromboembolism (VTE)
4.2 Global Rivaroxaban Market Size by Application
4.2.1 Global Rivaroxaban Market Size Overview by Application (2018-2029)
4.2.2 Global Rivaroxaban Historic Market Size Review by Application (2018-2023)
4.2.3 Global Rivaroxaban Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America Rivaroxaban Sales Breakdown by Application (2018-2023)
4.3.2 Europe Rivaroxaban Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific Rivaroxaban Sales Breakdown by Application (2018-2023)
4.3.4 Latin America Rivaroxaban Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa Rivaroxaban Sales Breakdown by Application (2018-2023)
5 North America Rivaroxaban by Country
5.1 North America Rivaroxaban Historic Market Size by Country
5.1.1 North America Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America Rivaroxaban Sales in Volume by Country (2018-2023)
5.1.3 North America Rivaroxaban Sales in Value by Country (2018-2023)
5.2 North America Rivaroxaban Forecasted Market Size by Country
5.2.1 North America Rivaroxaban Sales in Volume by Country (2024-2029)
5.2.2 North America Rivaroxaban Sales in Value by Country (2024-2029)
6 Europe Rivaroxaban by Country
6.1 Europe Rivaroxaban Historic Market Size by Country
6.1.1 Europe Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe Rivaroxaban Sales in Volume by Country (2018-2023)
6.1.3 Europe Rivaroxaban Sales in Value by Country (2018-2023)
6.2 Europe Rivaroxaban Forecasted Market Size by Country
6.2.1 Europe Rivaroxaban Sales in Volume by Country (2024-2029)
6.2.2 Europe Rivaroxaban Sales in Value by Country (2024-2029)
7 Asia-Pacific Rivaroxaban by Region
7.1 Asia-Pacific Rivaroxaban Historic Market Size by Region
7.1.1 Asia-Pacific Rivaroxaban Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific Rivaroxaban Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific Rivaroxaban Sales in Value by Region (2018-2023)
7.2 Asia-Pacific Rivaroxaban Forecasted Market Size by Region
7.2.1 Asia-Pacific Rivaroxaban Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific Rivaroxaban Sales in Value by Region (2024-2029)
8 Latin America Rivaroxaban by Country
8.1 Latin America Rivaroxaban Historic Market Size by Country
8.1.1 Latin America Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America Rivaroxaban Sales in Volume by Country (2018-2023)
8.1.3 Latin America Rivaroxaban Sales in Value by Country (2018-2023)
8.2 Latin America Rivaroxaban Forecasted Market Size by Country
8.2.1 Latin America Rivaroxaban Sales in Volume by Country (2024-2029)
8.2.2 Latin America Rivaroxaban Sales in Value by Country (2024-2029)
9 Middle East and Africa Rivaroxaban by Country
9.1 Middle East and Africa Rivaroxaban Historic Market Size by Country
9.1.1 Middle East and Africa Rivaroxaban Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa Rivaroxaban Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa Rivaroxaban Sales in Value by Country (2018-2023)
9.2 Middle East and Africa Rivaroxaban Forecasted Market Size by Country
9.2.1 Middle East and Africa Rivaroxaban Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa Rivaroxaban Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 Bayer
10.1.1 Bayer Company Information
10.1.2 Bayer Introduction and Business Overview
10.1.3 Bayer Rivaroxaban Sales, Revenue and Gross Margin (2018-2023)
10.1.4 Bayer Rivaroxaban Products Offered
10.1.5 Bayer Recent Development
10.2 J&J
10.2.1 J&J Company Information
10.2.2 J&J Introduction and Business Overview
10.2.3 J&J Rivaroxaban Sales, Revenue and Gross Margin (2018-2023)
10.2.4 J&J Rivaroxaban Products Offered
10.2.5 J&J Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 Rivaroxaban Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 Rivaroxaban Industrial Chain Analysis
11.4 Rivaroxaban Market Dynamics
11.4.1 Rivaroxaban Industry Trends
11.4.2 Rivaroxaban Market Drivers
11.4.3 Rivaroxaban Market Challenges
11.4.4 Rivaroxaban Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 Rivaroxaban Distributors
12.3 Rivaroxaban Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
